In an exclusive interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Vikas Bansi, Business Director - Healthcare, Himalaya Wellness Company, discusses how pharmaceutical companies are navigating the growing demand for OTC
.png)
India’s drug ingredient makers are facing a sharp rising chemical costs crisis, as surging prices of key inputs disrupt production and squeeze margins across the pharmaceutical supply chain.
The painkiller and antibiotic prices in India are set to rise slightly from April 1, following an annual revision linked to inflation.
India and Japan have signed a major agreement to invest JPY 275 billion in Maharashtra healthcare system, marking a significant step toward improving public health infrastructure in the state.
Uttar Pradesh pharma investment is gaining strong momentum as the state moves ahead with a INR2,500 crore plan to build a robust healthcare manufacturing ecosystem.
.png)
Sun Pharmaceutical Industries Limited has rolled out its semaglutide injection in India under the brands Noveltreat and Sematrinity, widening access to treatments for type 2 diabetes and chronic weight management.
Indian Pharma Companies have kicked off an aggressive race in generic semaglutide after the patent for the blockbuster diabetes and weight-loss drug expired on March 20, 2026.
India's pharma sector evolves with Biopharma SHAKTI Scheme, focusing on biologics, biosimilars, and advanced therapies to boost global competitiveness and healthcare.
.png)
Natco Pharma has just shaken up the India’s diabetes drug market with its launch of semaglutide at just INR 1,290 a month, making high end diabetes treatment far more affordable for millions.
Bharat Biotech is advancing vaccines to fight drug resistance, focusing on preventing hospital infections and reducing antibiotic use as antimicrobial resistance grows into a major global health threat.
.jpg)
, CDSCO.jpg)